公开(公告)号：US20230141284A1

公开(公告)日：2023-05-11

申请号：US17916268

申请日：2021-04-09

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Kazuhiko TAKEDA ,  Ryohei MIYATA ,  Tomoya KOIKE ,  Akira KATSUBE

IPC分类号： A61K31/437 ,  A61K39/395 ,  A61K31/573 ,  A61P35/00 ,  A61K31/635 ,  A61K31/7068 ,  A61K31/706 ,  A61P35/02 ,  A61P17/00 ,  A61P1/00 ,  A61K31/675 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/5377 ,  A61K31/685

CPC分类号： A61K31/437 ,  A61K39/3955 ,  A61K31/573 ,  A61P35/00 ,  A61K31/635 ,  A61K31/7068 ,  A61K31/706 ,  A61P35/02 ,  A61P17/00 ,  A61P1/00 ,  A61K31/675 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/5377 ,  A61K31/685 ,  A61K2039/505

摘要： A prescription capable of avoiding induction of inflammatory cytokine production caused by a STING agonistic compound in a cancer patient, when suppressing the progression of, suppressing the recurrence of and/or treating cancer by the STING agonistic compound, is provided. A prescription that a STING agonistic compound is administered in combination with an adrenal corticosteroid when suppressing the progression of, suppressing the recurrence of and/or treating cancer. Methods for avoiding an induction of inflammatory cytokine production by administering the prescription in combination with an adrenal corticosteroid when administering a STING agonistic compound at reduced dosage in combination with an anti-neoplastic agent.